ClinicalTrials.gg
Active, not recruitingNCT07193615AATDUpdated Sep 26, 2025

Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

An Early Phase 1 interventional study of YOLT-202 in Alpha-1 Antitrypsin Deficiency (AATD), sponsored by RenJi Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-26.

Sponsored by RenJi Hospital · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a single-arm, open-label, single-dose, dose-escalation exploratory study to evaluate the safety and tolerability of a single dose of YOLT-202 in patients with AATD and determine the optimal biologically active dose (OBD) of YOLT-202.

Read the detailed description

This is a single-arm, open-label, single-dose, dose-escalation exploratory study to evaluate the safety and tolerability of a single dose of YOLT-202 in patients with AATD, determine the OBD of YOLT-202, and preliminarily assess the impact of a single dose of YOLT-202 on changes in FEV1 and FEV1/FVC ratio from baseline after bronchodilator use.

Note: The OBD is defined as the dose achieving either a blood functional-AAT/total-AAT protein ratio of 50%-95% at Day 21 post-dose, or a blood total-AAT protein concentration ≥ 11 μM at Day 21 post-dose. OBD ≤ maximum tolerated dose (MTD).

In this study, the maximum screening period of the main study is 60 days, the treatment day is D0, and the safety follow-up period is up to Week 52 after administration. In the main study, when OBD is achieved, additional subjects will be added to the dose group (the sponsor and the investigator will jointly negotiate the specific number of subjects) for further verification. After completing safety follow-up, subjects may voluntarily receive a second dose of the investigational drug at the OBD level based on comprehensive assessments of efficacy, safety, and PK/PD data.

After the end of the main study, the subjects will undergo long-term follow-up.

02

Conditions studied

  • Alpha-1 Antitrypsin Deficiency (AATD)
03

In context

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

This study's planned enrollment of 18 is below the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.

Browse alpha 1-Antitrypsin Deficiency studies →

Lead sponsor

RenJi Hospital is the lead sponsor of 551 studies on the registry; 248 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (inclusive) aged ≥ 18 and ≤ 70 years old at the time of signing .
  • Diagnosed with AATD and genetically confirmed as homozygous PiZZ mutation.
  • Blood total AAT level \< 11 μM or equivalent protein in mg/dL.
  • Patients receiving augmentation therapy must be willing to discontinue it at least 6 weeks prior to signing the informed consent form (ICF) and throughout the study period, unless clinically indicated.

Exclusion criteria

Exclusion criteria

  • (BMI) > 35 kg/m2.
  • Patients who have undergone lung or liver transplantation, are on the waiting list for lung or liver transplantation, or have had lung volume reduction surgery (LVRS).
  • Clinical evidence of severe bronchiectasis, as judged by the investigator (e.g., excessive sputum production or recurrent infections requiring antibiotics [> 4 times per year]).
  • ≤ 30% of predicted value after bronchodilator use at screening
  • Liver disease with any of the following:

    • Measured liver stiffness (FibroScan) ≥ 10 kilopascals (kPa).
    • Known history of hepatic cirrhosis or associated complications (e.g., varices, ascites, hepatic encephalopathy).
    • ≥ F2 hepatic fibrosis in patients with prior liver .
    • (ALT) or aspartate aminotransferase (AST) > 1.5 times the (ULN).
    • Total > ULN; or > 2 times the ULN if Gilbert's syndrome is documented.
    • (INR) ≥ 1.2 at screening. If deemed appropriate by the investigator and/or the prescribing physician, anticoagulants may be discontinued for a or reversed with vitamin K. If necessary, a repeat INR \< 1.2 is acceptable.
    • surface antigen (HBsAg) positive.
    • virus (HCV) antibody positive. If HCV antibody is positive, HCV RNA PCR must be negative.
  • Allergy to the drugs contained in lipid nanoparticles (LNP) or LNP-mRNA vaccines, or previous history of adverse reactions to LNP-based drugs;
  • Smoking more than 5 cigarettes per day or consuming the equivalent amount of nicotine or nicotine replacement products within the past 6 months before screening.
  • History of alcohol abuse within the past 6 months before screening (drinking more than 14 units of alcohol per week [1 unit ≈ 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine]); or positive alcohol breath test at the time of screening or admission.
  • Patients with poorly controlled hypertension by conventional treatments (systolic blood pressure [SBP] ≥ 180 mmHg and/or diastolic blood pressure [DBP] ≥ 110 mmHg).
  • Patients with poorly controlled diabetes ( ≥ 9%).
  • Presence of (NYHA) class III-IV heart failure, \< 50%, or prolonged (female > 470 ms, male > 450 ms) at the time of screening.
  • Myocardial infarction, unstable angina pectoris, percutaneous coronary intervention, coronary artery bypass grafting, severe deep vein thrombosis or pulmonary embolism within 3 months before screening; poorly controlled severe arrhythmias within the past 3 months before screening, such as poorly controlled recurrent and highly symptomatic ventricular tachycardia, rapid ventricular response atrial fibrillation, or supraventricular tachycardia; or planned cardiac surgery or cardiac revascularization during the main study period.
  • Cerebrovascular accidents within 6 months before screening;
  • Known or suspected systemic viral, parasitic, or fungal infections, or active infections requiring expected antibiotic therapy within 14 days after screening.
  • (HIV) antibody positive at screening.
  • Anticoagulant therapy within 14 days before enrollment (such as warfarin, dabigatran, apixaban).
  • Patients with bleeding tendency or history of coagulation disorders (such as liver cirrhosis, malignant hematological diseases, antiphospholipid antibody syndrome);
  • Expected survival time less than 2 years.
  • History of malignant tumors within the past 5 years (excluding cured skin basal cell carcinoma, skin squamous cell carcinoma, cervical carcinoma in situ, low-grade prostate carcinoma in situ, and cured thyroid basal cell carcinoma).
  • History of drug abuse within the past 3 years.
  • Pregnant or lactating women.
  • Patients with other diseases in the blood system, digestive system, central nervous system, or endocrine system that the investigator believes will interfere with evaluation or limit participation in the trial.
  • Inability or unwillingness to cooperate or comply with pretreatment medication requirements or study procedures.
  • Any other condition deemed unsuitable for the clinical trial participation by the investigator.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Single arm

    Dose groups: 35mg, 45mg, 55mg, TBD (During the dose-escalation process, the investigator and the sponsor may decide, based on actual circumstances, whether to add new dose groups or repeat completed dose groups for the exploratory study).

    Drug: YOLT-202

Interventions

  • DrugYOLT-202

    The IP is administered intravenously at the predetermined dose; Administration frequency: Once

    Also known as: AATD-YOLT-202-001

06

What researchers measure

Primary outcomes

  1. Safety of YOLT-202 in subjects after administration

    Numbers and percentages of patients with adverse events (AE)

    Time frame: Baseline to 52 weeks post-dose

Secondary outcomes

  1. Pharmacokinetics parameter of YOLT-202

    Post-dose plasma concentration (Cmax)

    Time frame: 30 minutes pre-dose, 2 hours, 6 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours and 504 hours post-dose

  2. Pharmacokinetic (PK) parameter of YOLT-202

    Evaluate the time of maximum concentration (tmax)

    Time frame: 30 minutes pre-dose, 2 hours, 6 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours and 504 hours post-dose

  3. Pharmacokinetic (PK) parameter of YOLT-202

    To evaluate the area under curve (AUC)

    Time frame: 30 minutes pre-dose, 2 hours, 6 hours, 24 hours, 48 hours, 72 hours, 168 hours, 336 hours and 504 hours post-dose

  4. Pharmacokinetic (PK) parameters of YOLT-202

    To evaluate elimination half-life (t1/2)

    Time frame: 30 minutes pre-dose, 2 hours, 6 hours, 24 hours, 48 hours, 72 hours,168 hours,336 hours and 504 hours post-dose

  5. Changes in blood AAT protein level

    Total -AAT level over time

    Time frame: Weeks 1, 2, 3 and 52 post-dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jan 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Sep 26, 2025
StartActual
Jun 18, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Mar 2027
Last update
Sep 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07193615
Lead sponsor
RenJi Hospital
Responsible party
Sponsor
First posted
Sep 26, 2025
Start date
Jun 18, 2025
Primary completion
Jan 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion